Navigate peer-reviewed breakthroughs by pharmacological class, genetic target, circulating biomarker, or diagnostic modality. Select any clinical entity to inspect all linked studies.
The reason you're taking Ozempic or Wegovy matters during pregnancy, with underlying diabetes potentially posing a greater risk than the medication itself. This study challenges the previously held, often generalized, assumption that GLP-1 medications alone are responsible for pregnancy complications.
3/5 Observational
Evidence Meter · 3/5
Real-World Observation
Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.
AI-guided discovery of the natural molecule BRP offers a novel, potentially better-tolerated approach to obesity treatment than existing medications. BRP represents a potential 'Ozempic-like' treatment for obesity that may circumvent common digestive side effects and muscle loss often associated with current GLP-1 agonists.
2/5 Preclinical
Evidence Meter · 2/5
Animal & Preclinical Data
Demonstrated in living animal models before large-scale human safety and dosing trials begin.
Oral semaglutide reduced the risk of first plus subsequent 3-P MACE vs placebo (inactive comparison treatment), highlighting the benefit of oral semaglutide in reducing the total burden of clinical morbidity and risk of death in this high-risk population. This was a prespecified secondary analysis of the double-blind, placebo-controlled, event-driven, phase 3b SOUL randomized clinical trial, conducted from June 2019 to September 2024 with a median (IQR) follow-up of 49.5 (44.0-54.9) months at 444 centers in 33 countries.
5/5 Gold Standard
Evidence Meter · 5/5
Gold-Standard Human Evidence
Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.
In patients with MASH, 48 weeks of pemvidutide treatment led to significant reductions in non-invasive tests of MASH inflammation and fibrosis (tissue scarring), suggesting continued improvement in liver health. These data warrant the continued investigation of pemvidutide in a Phase 3 trial.
5/5 Gold Standard
Evidence Meter · 5/5
Gold-Standard Human Evidence
Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.
1 min read·The Lancet Gastroenterology & Hepatology·
For related endpoints, resistance exercise reduced loss of appendicular lean soft tissue mass (T = -3.55 kg, T+REx = -2.92 kg, P < 0.001). Upper and lower body muscle strength decreased with tirzepatide (bench press -4.09 kg, lat pulldown -4.42 kg, knee extension -4.42 kg) but increased with T+REx (+4.68 kg, +8.58 kg, +5.88 kg, respectively, all P < 0.001 versus tirzepatide).
5/5 Gold Standard
Evidence Meter · 5/5
Gold-Standard Human Evidence
Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.
After 52 weeks, the mean change in PAWP during exercise was -9.8 (95% confidence interval (CI): -11.3 to -8.2) mmHg with semaglutide and +0.9 (95% CI: -1.3 to 3.0) mmHg with placebo (estimated difference, -10.6 mmHg; 95% CI: -13.3 to -8.0; P < 0.0001). The results from this trial indicate that, in patients with HFpEF and obesity, treatment with semaglutide reduced left heart filling pressures during exercise and at rest and was associated with hemodynamic HFpEF remission in over half of treated patients.
5/5 Gold Standard
Evidence Meter · 5/5
Gold-Standard Human Evidence
Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.
Improvements in LA reservoir strain and LV filling dynamics were associated with reductions in exercise PAWP (r=-0.46, P<0.001 and r=-0.65, P<0.0001, respectively). With respect to other prespecified CMR endpoints, semaglutide reduced LV mass, restored more physiologic LV geometry, and improved right ventricular function and biventricular myocardial mechanics.
5/5 Gold Standard
Evidence Meter · 5/5
Gold-Standard Human Evidence
Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.
Genetic variation influences glycemic response to glucose-lowering medications, with SLC2A2 emerging as a genetic factor that modulates sulfonylurea response. These findings warrant further study to evaluate whether low-response allele carriers would benefit from alternative glucose-lowering therapies to advance precision diabetes care.
5/5 Gold Standard
Evidence Meter · 5/5
Gold-Standard Human Evidence
Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.
In Japanese adults with obesity disease, once-daily orforglipron resulted in statistically superior reductions in bodyweight versus placebo (inactive comparison treatment), with a safety profile consistent with that of other GLP-1 receptor agonists. Orforglipron, a small-molecule, non-peptide, oral GLP-1 receptor agonist, has shown bodyweight reduction and cardiometabolic benefits in adults with obesity across Phase 3 trials globally.
5/5 Gold Standard
Evidence Meter · 5/5
Gold-Standard Human Evidence
Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.
This Medical News article discusses an analysis of cardiovascular benefits and safety of semaglutide use in trial participants with frailty, defined by accumulated age-related health deficits. Published in JAMA, these peer-reviewed endocrinology findings provide quantitative evidence to inform clinical risk stratification, therapeutic decision-making, and follow-up trial design.
3/5 Observational
Evidence Meter · 3/5
Real-World Observation
Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.
In adults with T1D and overweight/obesity, acmopatide was associated with improved glycemic control and clinically meaningful weight loss without DKA or severe hypoglycemia events. To evaluate the efficacy (real-world effectiveness in the trial) and safety of acmopatide, a signal-biased glucagon-like peptide 1/glucose-dependent insulinotropic polypeptide receptor agonist, in adults with type 1 diabetes (T1D) and overweight/obesity.
5/5 Gold Standard
Evidence Meter · 5/5
Gold-Standard Human Evidence
Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.
This study uses comprehensive prescription drug monitoring program data to describe compounded weight-loss prescriptions, rates of self-payment, out-of-state dispensing, and the ingredients contained in compounded GLP-1s. Published in JAMA, these peer-reviewed nephrology findings provide quantitative evidence to inform clinical risk stratification, therapeutic decision-making, and follow-up trial design.
3/5 Observational
Evidence Meter · 3/5
Real-World Observation
Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.
Obesity in children is associated with chronic disease, such as hypertension, and with poor quality of life. Evidence-based treatment for obesity in children includes intensive health behavior and lifestyle treatment, and pharmacotherapy may provide additional benefit, although short- and long-term safety and efficacy (real-world effectiveness in the trial) data are limited.
5/5 Gold Standard
Evidence Meter · 5/5
Gold-Standard Human Evidence
Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.
In this safety assessment, SAEs were reported less frequently with semaglutide than placebo (inactive comparison treatment), with corresponding patterns observed for treatment discontinuations and AESIs. No unexpected safety concerns were identified across the spectrum of eGFR represented in the FLOW trial.
5/5 Gold Standard
Evidence Meter · 5/5
Gold-Standard Human Evidence
Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.
We take a critical historical perspective, charting the highs and lows of obesity medication development and examining the scientific, regulatory, and societal factors that have slowed or impeded the translation of pharmacological advances into safe, effective, and widely accepted treatments for obesity. Reflecting this paradigm shift, WHO issued global guidelines and included GLP-1 receptor agonists in the Essential Medicines List, albeit for a narrowly defined population.
3/5 Observational
Evidence Meter · 3/5
Real-World Observation
Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.
Interpretation is limited by the observational design, absence of a comparator group, self-pay population and 6-month follow-up. These findings support the feasibility of delivering structured, digitally enabled obesity pharmacotherapy at scale and provide prospective real-world implementation evidence for this care model.
5/5 Gold Standard
Evidence Meter · 5/5
Gold-Standard Human Evidence
Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.
UBT251 produced weight reduction with cardiometabolic improvements and an acceptable safety profile, supporting Phase 3 evaluation. UBT251 is a novel triple agonist targeting glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, and glucagon receptors.
5/5 Gold Standard
Evidence Meter · 5/5
Gold-Standard Human Evidence
Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.
1 min read·Cell Metabolism·
Patient & Student Companion
Everyday Lab & Drug Translator
Instant plain-English guides for common blood tests and prescriptions—what normal ranges mean, what high/low values signal, and what to ask your clinician.
Lab Marker3-Month Blood Sugar
HbA1c
Measures the percentage of red blood cell hemoglobin coated with glucose over roughly 90 days.
Normal: below 5.7% · Prediabetes: 5.7%–6.4%
6.5% or higher on two tests diagnoses diabetes; very low values can occur alongside hypoglycemia or hemolytic anemia.
Ask your doctor: “Does my HbA1c match my daily fasting/post-meal glucose trends?”
Estimated glomerular filtration rate—how many milliliters of blood your kidneys filter every minute.
Healthy adult filter rate: 90+ mL/min/1.73m²
Values persistently below 60 for 3+ months (or elevated urine albumin) mark chronic kidney disease; single dips can simply reflect dehydration or NSAID use.
Ask your doctor: “Should we pair eGFR with a urine albumin-to-creatinine test (uACR)?”